Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers – Eli Lilly and Company

1. Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers  Eli Lilly and Company
2. Meet One Amgen Scientist Who Helped Crack the “Undruggable” KRAS Code  Amgen
3. D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors  OncLive
4. FDA grants breakthrough therapy status to Lilly’s lung cancer drug olomorasib  StreetInsider
5. D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers  PR Newswire

Continue Reading